Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/10/21
Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?24/7 Wall Street • 01/19/21
Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock OptionsZacks Investment Research • 12/23/20
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx ConferenceGlobeNewsWire • 11/16/20
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/04/20
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/29/20
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic DermatitisGlobeNewsWire • 10/20/20
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business HighlightsGlobeNewsWire • 08/07/20
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 08/06/20
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic DermatitisGlobeNewsWire • 07/07/20
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19GlobeNewsWire • 06/17/20